» Articles » PMID: 34045900

Absolute Circulating Leukemic Cells As a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2021 May 28
PMID 34045900
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hemorrhagic complications are the most common cause of early death in patients with APL and remain a major challenge in the management of APL. Early fatal bleeding events occur not only in high-risk but also in non-high-risk acute promyelocytic leukemia (APL) patients with normal or low WBC counts.

Objectives And Methods: To demonstrate the role of the absolute number of circulating leukemic cells in early bleeding events in APL patients. Clinical and laboratory characteristics of 149 patients newly diagnosed with APL were obtained from medical records and retrospectively investigated.

Results: In this study, circulating absolute leukemic cells were positively correlated with the WBC count (r=0.9813, <0.001) in all patients with APL, and importantly, they were strongly associated with significant bleeding events in non-high-risk patients. Multivariate logistic regression analysis showed that the absolute number of leukemia cells was an independent risk factor for significant bleeding events in APL patients. A cut-off value of 2.59×10/L for circulating leukemic cells to predict significant bleeding events in APL patients was obtained by ROC curve analysis. We further confirmed that the significant bleeding rate of patients with non-high-risk APL was statistically increased when the absolute number of circulating leukemic cells was ≥2.59×10/L.

Conclusion: Circulating leukemic cell content has great clinical value for predicting early bleeding events in APL patients, especially in non-high-risk APL.

Citing Articles

Acute promyelocytic leukemia with additional chromosome abnormalities in a patient positive for HIV: A case report and literature review.

Li X, Li M, Wang L, Tian J, Shi Z, Song K Oncol Lett. 2024; 27(6):274.

PMID: 38694571 PMC: 11061549. DOI: 10.3892/ol.2024.14407.


The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management.

Hermsen J, Hambley B Cancers (Basel). 2023; 15(13).

PMID: 37444587 PMC: 10340352. DOI: 10.3390/cancers15133477.

References
1.
Minamiguchi H, Fujita H, Atsuta Y, Asou N, Sakura T, Ueda Y . Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol. 2020; 99(12):2787-2800. DOI: 10.1007/s00277-020-04245-6. View

2.
Park J, Qiao B, Panageas K, Schymura M, Jurcic J, Rosenblat T . Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011; 118(5):1248-54. PMC: 3790946. DOI: 10.1182/blood-2011-04-346437. View

3.
Norgaard J, Friis L, Kristensen J, Severinsen M, Molle I, Marcher C . Addressing the room for improvement in management of acute promyelocytic leukemia. Eur J Haematol. 2019; 102(6):479-485. DOI: 10.1111/ejh.13229. View

4.
Fogarty P, Tarantino M, Brainsky A, Signorovitch J, Grotzinger K . Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2011; 28(1):79-87. DOI: 10.1185/03007995.2011.644849. View

5.
Song Y, Peng P, Qiao C, Zhang R, Li J, Lu H . Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia. Onco Targets Ther. 2017; 10:4917-4924. PMC: 5640392. DOI: 10.2147/OTT.S144438. View